Close Menu

People in the News

Jan 12, 2021

MeMed: Troy Boutelle

MeMed has appointed Troy Boutelle as VP of commercial, North America and GM, US. He will lead Haifa, Israel-based MeMed's operation in North America from Boston. He has 20 years of leadership experience at life science companies including at Eurofins-Viracor where he was its VP of sales of marketing prior to joining MeMed. He previously was commercial lead at Thermo Fisher Scientific where he led the commercial team for the Americas microbiology team.

Jan 08, 2021

Qiagen: Toraf Haag

Qiagen said Toraf Haag has been appointed to its supervisory board and audit committee. Since 2018 Haag has served as chairman of the management board of Germany-based global technology firm Voith. Before joining Voth in 2016 as chief financial officer, Haag served for more than 11 years as CFO and an executive committee member at Lonza Group.

Jan 06, 2021

DermTech: Ray Akhavan

DermTech has appointed Ray Akhavan as its general counsel. Most recently, Akhavan served as associate general counsel and chief intellectual property counsel at Ancestry. Prior to Ancestry, Akhavan served as general counsel and chief intellectual property counsel at Caris Life Sciences. He has also worked as a research biologist at the National Institutes of Health and as a patent examiner at the US Patent and Trademark Office. 

Jan 05, 2021

Novacyt: James McCarthy, Anthony Dyer

Clinical diagnostics firm Novacyt has appointed James McCarthy as its CFO and Anthony Dyer to a new role as its chief corporate development officer. McCarthy will become a board director, subject to shareholder approval at the company's annual general meeting. Dyer will remain a board director until then.

McCarthy has held senior positions in listed and private equity-backed businesses. He was CFO of Flint Group, and of Brambles' Europe, Middle East, and Africa-based Commonwealth Handling Equipment Pool (CHEP) business before being promoted to president of CHEP’s European team.

McCarthy trained as an accountant with Dairygold and has worked for Unilever and ICI, among other companies.

Jan 05, 2021

Biodesix: Ryan Siurek

Ryan Siurek has joined Biodesix as chief accounting officer. He was previously SVP, chief accounting officer and controller of Vail Resorts. Prior to that, he held various accounting and finance roles at Sprint, including VP controller and chief accounting officer, and VP, divisional CFO for the prepaid and wholesale and enterprise solutions divisions.

Jan 05, 2021

Exact Sciences: Mark Stenhouse, Pat Setji

Exact Sciences announced that Mark Stenhouse left his position as general manager of the company's screening business on Jan. 5. He will be succeeded by Pat Setji, Exact's vice president of business operations.

Over the last 20 years Setji has served in multiple sales and marketing leadership roles at Pfizer, Eli Lilly, and Exact. In connection with his departure, Stenhouse will assist with the transition as an advisor, and will remain with Exact as a non-executive employee through March 31.

Jan 05, 2021

SomaLogic: Jason Cleveland, Angela Bakker Lee, Tracy Hervey, David McGovern

SomaLogic this week announced several new executive appointments.

Jason Cleveland will be the company's new chief technology officer. He joined SomaLogic in 2015 as a consultant and became a principal research fellow in 2018. Prior to SomaLogic, he was cofounder, chairman, and CEO of Asylum Research, a manufacturer of atomic force microscopes (AFM). He began his career at Digital Instruments, an early AFM maker. Cleveland has a PHD in physics from the Universiy of California, Santa Barbara and is a fellow of the American Physical Society.

SomaLogic has also appointed Angela Bakker Lee as its executive VP for healthcare markets, Tracy Hervey as executive VP for life science markets, and David McGovern as senior VP of marketing.

Prior to SomaLogic, Bakker Lee most recently served as chief strategy officer at Quid, an AI text analytics platform provider. Bakker Lee also previously led IBM's Global Business Services Healthcare for North America. Prior to IBM, Bakker Lee spent 15 years with ZS Associates, a management consulting firm specializing in commercial strategy and sales and marketing operations. Before ZS Associates, she worked at Molecular Applications Group.

Hervey most recently served as chief commercial officer at Amplity Health. Prior to Amplity Health, she served as VP of global accounts at Icon. Before Icon, Hervey held sales leadership roles at data science firm Iqvia and PPD, a global contract research organization.

McGovern previously served as strategic payer marketing lead at Pfizer. Prior to Pfizer, McGovern served as VP of marketing and business development at Change Healthcare. Before Change Healthcare, he held various leadership roles in global commercial development, marketing, and market access at Johnson & Johnson, Merck, and Otsuka. McGovern has also served as VP of marketing at Nupathe, which was later sold to Teva Pharmaceuticals.

Jan 04, 2021

Color: Claire Vo, Emily Reuter, Ashley Chandler

Color has added three individuals to its upper management in connection with a $167 million Series D financing announced this week. Claire Vo will be Color's new chief product officer, having previously held the same title at Optimizely. Emily Reuter is Color's new vice president of strategy and operations, joining the company from Uber, where she was head of investor relations. Ashley Chandler has been named Color's vice president of marketing, and joins the company from Stripe, where she led several marketing functions through a period of rapid growth.

Dec 23, 2020

Diaceutics: Deborah Davis

Diaceutics, a data analytics and services provider for precision medicine, has appointed Deborah Davis as non-executive chair effective Jan. 4, 2021. Davis spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay; and technology companies Symantec and Verizon. She currently holds a number of non-executive director and board committee positions including with International Personal Finance, IDEX Biometrics, the Institute of Directors UK, and Which? Ltd.

Dec 22, 2020

Biological Dynamics: Kevin Han

Biological Dynamics, a company developing cancer early detection products, has named Kevin Han as chief financial officer. Previously, Han held positions in investor relations, corporate communications, and corporate sustainability strategies at Bio-Rad Laboratories. Prior to that, he was a portfolio manager for Lombard Odier Asset Management. Han started his career at Morgan Stanley and, later, Goldman Sachs, where he covered the medical technology and diagnostics sectors.

Dec 22, 2020

Danaher: Jose-Carlos Gutierrez-Ramos

Danaher has named Jose-Carlos Gutierrez-Ramos as its chief scientific officer and senior VP. He will be an executive officer of the company tasked with defining Danaher's science and technology strategy. He joins Danaher from Abbvie, where he served as head of global drug discovery. Gutierrez-Ramos also previously served as president and CEO of Repertoire Immune Medicines and Synlogic, and prior to that held R&D positions at Pfizer, GlaxoSmithKline, Avidia, and Millennium Pharmaceuticals. He also was a professor at Harvard Medical School in the Department of Genetics and a professor for the Spanish Scientific Research Council.

Dec 16, 2020

Abviris: Roman Niedbal

Abviris has appointed Roman Niedbal as its CEO to spearhead the further development and expansion of its point-of-care solutions. Niedbal was previously vice president of marketing and medical innovation at Sysmex Europe where he held various senior management positions for almost 10 years. With Abviris CFO Sven Klose, Niedbal will lead a new business development team that is seeking global strategic partners.

Dec 16, 2020

MeMed: Chris Hibberd

Israeli infectious disease company MeMed said Chris Hibberd has joined its board of directors. Hibbert is CEO and Executive Chairman of Nucleix. Before that, he was CEO and Cofounder of Astute Medical, which was acquired by BioMérieux. Previously, he was SVP of Corporate Development at Biosite.

Dec 15, 2020

Gradientech: Gunnar Kahlmeter, Jeffrey Bender, Holger Rhode

Swedish diagnostics company Gradientech has appointed Gunnar Kahlmeter, Jeffrey Bender, and Holger Rhode to its scientific advisory board. Kahlmeter is an expert in antibiotic resistance and antimicrobial susceptibility testing and chaired the European Committee on Antimicrobial Susceptibility Testing, EUCAST, for more than a decade. He is also former president of the European Society of Clinical Microbiology and Infectious Diseases and currently leads the EUCAST Development Laboratory and National Reference Laboratory on phenotypic susceptibility testing.

Bender is an infection disease physician and medical microbiologist at Children's Hospital Los Angeles, while Rhode is a senor physician and deputy head of the Institute for Medical Microbiology, Virology, and Hygiene at the Universitätsklinikum Hamburg-Eppendorg.

Dec 14, 2020

Guardant Health: Michael Bell

Guardant Health has named Michael Bell as CFO effective Jan. 4, 2021. He replaces Derek Bertocci who is retiring. Bell has more than 25 years of international finance and accounting experience and has worked in clinical diagnostics, pharma, and public accounting. He was most recently CFO of CareDx and was formerly CFO for Metabiota, Singulex, and Novartis Diagnostics.

Dec 14, 2020

Danaher: Jennifer Honeycutt

Danaher announced it has appointed Jennifer Honeycutt as executive VP, responsible for Beckman Coulter Life Sciences, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and Sciex. Previously, Honeycutt was a VP and group executive overseeing Pall, IDT, and the Danaher Life Sciences platform in China, as well as the president of Pall. From 2013 to 2016, she was president of Beckman Coulter Life Sciences. She joined Danaher in 1999 and served in general management roles at Hach Ultra Analytics, Anderson Instrument Company, and Linx Printing Technologies.

Dec 10, 2020

CareDx: Michael Bell, Marcel Konrad

CareDx said that CFO Michael Bell has notified the company of his intent to resign, effective Dec. 31. The firm has appointed Marcel Konrad to serve as interim CFO, effective upon Bell's resignation. 

Konrad has served as vice president and corporate controller at CareDx since August 2018. Prior to joining the company, he served in various capacities at Santen between November 2013 and July 2018, including as CFO for Santen USA, and as global head of R&D finance and CFO for Santen Ventures. Prior to that, Konrad worked for Novartis for nine years in both Switzerland and the US in various roles. 

Dec 10, 2020

Biofidelity: Robert Osborne

Biofidelity has appointed Robert Osborne as its chief operating officer. Osborne previously served as senior VP of technology and assay development at Inivata. Prior to Inivata, Osborne served as principal staff scientist at the Wellcome Trust Sanger Institute, director of technology development at its spinout company, 14M Genomics, and director of research at Population Genetics Technologies.

Dec 09, 2020

Micronoma: Martin Blaser, Leena Das-Young, Ravid Straussman, Rob Knight,

Micronoma has formed its scientific advisory board, which includes Martin Blaser, Leena Das-Young, Ravid Straussman, and Rob Knight.

Blaser currently serves as the Henry Rutgers chair of the Human Microbiome, professor of medicine and pathology, and as director of the Center for Advanced Biotechnology and Medicine at Rutgers University.

Das-Young previously served as the head of late-phase oncology development at Pfizer. She has also served in senior leadership roles at Guardant Health.

Straussman is a principal investigator at the Weizmann Institute in Rehovot, Israel.

Knight is a cofounder of Micronoma and currently serves as the founding director of the Center for Microbiome Innovation and professor of pediatrics and computer science & engineering at the University of California, San Diego.

Dec 09, 2020

Ares Genetics: Arne Materna, Andreas Posch, Achim Plum

OpGen subsidiary Ares Genetics has announced founding CEO and Managing Director Andreas Posch and Managing Director Achim Plum will step down from their positions, effective Dec. 31. They will both stay on as special advisors throughout 2021 to ensure a smooth transition.

Arne Materna has been appointed managing director and CEO, effective Jan. 1. Materna previously served as vice president, products at CosmosID and has held leadership roles at Qiagen, CLCbio, and Pacific Biosciences. He has particular expertise in microbiology and next-generation sequencing and has experience developing bioinformatics platforms and products.

Dec 03, 2020

Infinity Biologix: Amit Bhalla

Infinity Biologix  has appointed Amit Bhalla as its vice president and CFO. He will lead the company's financial operations as it enters its next phase of growth after spinning out from Rutgers University in August. IBX is a central lab that provides sample collection and processing, storage, analytical services, and scientific and technical support. It received Emergency Use Authorization from the US Food and Drug Administration for its saliva-based test for detecting SARS-CoV-2 in April.

Balla joins the firm after more than 20 years of experience on Wall Street and in the healthcare industry. He was most recently senior healthcare analyst at Lord, Abbett and previously had senior roles at Becton Dickinson, Citigroup, Morgan Stanley, and Johnson & Johnson.

Dec 01, 2020

Diadem: Tamas Bartfai

Alzheimer's disease test developer Diadem has named Tamas Bartfai, a neuroscientist and Alzheimer's disease researcher, as chair of its medical advisory board.

Bartfai is an international expert in the development of drugs targeting neurological diseases, including Alzheimer’s disease, the firm said.

In the past, he was a professor, chairman of molecular and integrative neurosciences, and director at the Dorris Neuroscience Center at the Scripps Research Institute, and an adjunct professor at Stockholm University, the University of Oxford, and the University of Pennsylvania.

Bartfai has served as a drug development senior executive or consultant to pharmaceutical companies, including AstraZeneca, Roche, Novartis, and Pfizer. He has also been a consultant to biotech venture capitalists and helped launch a number of biotech startups.

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Nov 25, 2020

Enzo Biochem: Ian Walters

Ian Walters has been appointed to the board of directors of Enzo Biochem. He is the CEO and director of Portage Biotech, a biopharmaceutical firm developing immuno-oncology treatments. Previously, he was executive director of global oncology clinical research and business development at Bristol-Myers Squibb and medical director at Millennium Pharmaceuticals. Walters holds an MBA from the Wharton School of the University of Pennsylvania and an MD from Albert Einstein College of Medicine.

Nov 23, 2020

Thermo Fisher Scientific: Alexandra Keith

Alexandra Keith has been elected to the board of directors of Thermo Fisher Scientific. She is the CEO of Procter & Gamble's global beauty business and a member of P&G's global leadership council. Over the past 30 years, she has served in a variety of roles at P&G, including in manufacturing, logistics, communications, and product innovation.

Pages